{"id":62107,"date":"2026-04-01T21:07:22","date_gmt":"2026-04-01T13:07:22","guid":{"rendered":"https:\/\/flcube.com\/?p=62107"},"modified":"2026-04-01T21:07:24","modified_gmt":"2026-04-01T13:07:24","slug":"otsuka-pharmaceutical-to-acquire-transcend-therapeutics-for-up-to-1-225-billion-to-expand-neuropsychiatric-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62107","title":{"rendered":"Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Expand Neuropsychiatric Pipeline"},"content":{"rendered":"\n<p><strong>Otsuka Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/OTSKY:OTCMKTS\">OTCMKTS: OTSKY<\/a>) announced plans to fully acquire <strong>US-based Transcend Therapeutics, Inc.<\/strong> in a transaction valued at up to <strong>USD 1.225 billion<\/strong>, expected to close in the <strong>second quarter of 2026<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-structure\">Transaction Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Amount<\/th><th>Terms<\/th><\/tr><\/thead><tbody><tr><td><strong>Upfront Payment<\/strong><\/td><td>USD 700 million<\/td><td>Payable upon closing in Q2 2026<\/td><\/tr><tr><td><strong>Contingent Consideration<\/strong><\/td><td>USD 525 million<\/td><td>Milestone-based payments tied to future sales of investigational assets<\/td><\/tr><tr><td><strong>Total Potential Value<\/strong><\/td><td>USD 1.225 billion<\/td><td>Combined upfront and milestone payments<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-target-company-profile\">Target Company Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Founded<\/strong>: 2021<\/li>\n\n\n\n<li><strong>Headquarters<\/strong>: United States<\/li>\n\n\n\n<li><strong>Stage<\/strong>: Clinical-stage biotechnology company<\/li>\n\n\n\n<li><strong>Focus<\/strong>: Rapid-acting therapies for neuropsychiatric conditions<\/li>\n\n\n\n<li><strong>Lead Asset<\/strong>: TSND-201 (methylone) \u2013 a rapid-acting neuroplastogen<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-lead-asset-tsnd-201-methylone\">Lead Asset \u2013 TSND-201 (Methylone)<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-mechanism-of-action\">Mechanism of Action<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target<\/strong>: Monoamine transporters (serotonin, norepinephrine, dopamine)<\/li>\n\n\n\n<li><strong>Effect<\/strong>: Promotes monoamine release, increasing synaptic concentrations<\/li>\n\n\n\n<li><strong>Outcome<\/strong>: Rapid and sustained enhancement of neuroplasticity<\/li>\n\n\n\n<li><strong>Key Differentiator<\/strong>: <strong>Non-hallucinogenic<\/strong> \u2013 does not act on serotonin 5-HT2A receptor responsible for psychedelic effects<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-development-indications\">Development Indications<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Primary<\/strong>: Post-traumatic stress disorder (PTSD)<\/li>\n\n\n\n<li><strong>Secondary<\/strong>: Other psychiatric disorders<\/li>\n\n\n\n<li><strong>Status<\/strong>: Clinical development stage<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-otsuka-pharmaceutical\">For Otsuka Pharmaceutical<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Expansion<\/strong>: Adds innovative rapid-acting neuropsychiatric asset to existing CNS portfolio<\/li>\n\n\n\n<li><strong>Market Opportunity<\/strong>: Addresses significant unmet need in PTSD treatment with novel mechanism<\/li>\n\n\n\n<li><strong>Competitive Positioning<\/strong>: First-mover advantage in non-hallucinogenic neuroplastogens<\/li>\n\n\n\n<li><strong>Geographic Diversification<\/strong>: Strengthens U.S. presence in high-growth neuropsychiatric market<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>PTSD Treatment Gap<\/strong>: Current treatments show limited efficacy and slow onset of action<\/li>\n\n\n\n<li><strong>Neuroplasticity Focus<\/strong>: Emerging therapeutic paradigm showing promise across multiple psychiatric conditions<\/li>\n\n\n\n<li><strong>Regulatory Pathway<\/strong>: Potential for accelerated approval based on novel mechanism and unmet medical need<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-amp-operational-impact\">Financial &amp; Operational Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Integration Timeline<\/strong>: Expected to complete integration within 12 months post-closing<\/li>\n\n\n\n<li><strong>R&amp;D Investment<\/strong>: Otsuka plans to accelerate clinical development with expanded resources<\/li>\n\n\n\n<li><strong>Commercial Strategy<\/strong>: Leverage Otsuka&#8217;s established psychiatric franchise for potential commercialization<\/li>\n\n\n\n<li><strong>Risk Mitigation<\/strong>: Contingent payment structure aligns acquisition cost with clinical and commercial success<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the acquisition transaction, clinical development, and commercial potential for TSND-201. Actual results may differ due to risks including regulatory approvals, clinical trial outcomes, and integration challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Otsuka Pharmaceutical Co., Ltd. (OTCMKTS: OTSKY) announced plans to fully acquire US-based Transcend Therapeutics, Inc&#8230;.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2246,439,4668],"class_list":["post-62107","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-otcmkts-otsky","tag-otsuka-pharmaceutical","tag-transcend-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Expand Neuropsychiatric Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Otsuka Pharmaceutical Co., Ltd. (OTCMKTS: OTSKY) announced plans to fully acquire US-based Transcend Therapeutics, Inc. in a transaction valued at up to USD 1.225 billion, expected to close in the second quarter of 2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62107\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Expand Neuropsychiatric Pipeline\" \/>\n<meta property=\"og:description\" content=\"Otsuka Pharmaceutical Co., Ltd. (OTCMKTS: OTSKY) announced plans to fully acquire US-based Transcend Therapeutics, Inc. in a transaction valued at up to USD 1.225 billion, expected to close in the second quarter of 2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62107\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-01T13:07:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-01T13:07:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62107#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62107\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Expand Neuropsychiatric Pipeline\",\"datePublished\":\"2026-04-01T13:07:22+00:00\",\"dateModified\":\"2026-04-01T13:07:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62107\"},\"wordCount\":338,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"OTCMKTS: OTSKY\",\"Otsuka Pharmaceutical\",\"Transcend Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62107#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62107\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62107\",\"name\":\"Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Expand Neuropsychiatric Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-01T13:07:22+00:00\",\"dateModified\":\"2026-04-01T13:07:24+00:00\",\"description\":\"Otsuka Pharmaceutical Co., Ltd. (OTCMKTS: OTSKY) announced plans to fully acquire US-based Transcend Therapeutics, Inc. in a transaction valued at up to USD 1.225 billion, expected to close in the second quarter of 2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62107#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62107\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62107#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Expand Neuropsychiatric Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Expand Neuropsychiatric Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Otsuka Pharmaceutical Co., Ltd. (OTCMKTS: OTSKY) announced plans to fully acquire US-based Transcend Therapeutics, Inc. in a transaction valued at up to USD 1.225 billion, expected to close in the second quarter of 2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62107","og_locale":"en_US","og_type":"article","og_title":"Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Expand Neuropsychiatric Pipeline","og_description":"Otsuka Pharmaceutical Co., Ltd. (OTCMKTS: OTSKY) announced plans to fully acquire US-based Transcend Therapeutics, Inc. in a transaction valued at up to USD 1.225 billion, expected to close in the second quarter of 2026.","og_url":"https:\/\/flcube.com\/?p=62107","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-01T13:07:22+00:00","article_modified_time":"2026-04-01T13:07:24+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62107#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62107"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Expand Neuropsychiatric Pipeline","datePublished":"2026-04-01T13:07:22+00:00","dateModified":"2026-04-01T13:07:24+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62107"},"wordCount":338,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["OTCMKTS: OTSKY","Otsuka Pharmaceutical","Transcend Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62107#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62107","url":"https:\/\/flcube.com\/?p=62107","name":"Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Expand Neuropsychiatric Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-01T13:07:22+00:00","dateModified":"2026-04-01T13:07:24+00:00","description":"Otsuka Pharmaceutical Co., Ltd. (OTCMKTS: OTSKY) announced plans to fully acquire US-based Transcend Therapeutics, Inc. in a transaction valued at up to USD 1.225 billion, expected to close in the second quarter of 2026.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62107#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62107"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62107#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Expand Neuropsychiatric Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62107","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62107"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62107\/revisions"}],"predecessor-version":[{"id":62108,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62107\/revisions\/62108"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62107"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62107"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62107"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}